DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance

Oncotarget

Volumn 6, Issue 4, 2015, Pages 2134-2147

  Huber, Roland M ^a   Lucas, Jared M ^a   Gomez Sarosi, Luis A ^a   Coleman, Ilsa ^a   Zhao, Song ^a   Coleman, Roger ^a   Nelson, Peter S ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Microenvironment; Paracrine; Prostate cancer; Resistance; Treatment

Indexed keywords

BLEOMYCIN; DNA; DOCETAXEL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; MITOXANTRONE; PROTEIN GFRA1; PROTEIN RET; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TAXOID; TRANSCRIPTOME;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; DNA DAMAGE; DRUG TARGETING; FIBROBLAST; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; CELL SURVIVAL; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; RADIATION RESPONSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION (PROCESS); TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; HUMANS; MALE; MITOXANTRONE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TAXOIDS; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84923013040     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3040     Document Type: Article

References (34)

1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N and European Association of U. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014; 65(1):124-137.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F and Mottet N. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014; 65(2):467-479.
3. Mottet N, Clarke N, De Santis M, Zattoni F, Morote J and Joniau S. Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? BJU Int. 2014.
4. Gondos A, Bray F, Hakulinen T, Brenner H and Group ESW. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. Ann Oncol. 2009; 20(3):564-573.
5. Gilbert LA and Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010; 143(3):355-366.
6. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L and Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012.
7. Lin L, Doherty D, Lile J, Bektesh S and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993; 260(5111):1130-1132.
8. Airaksinen MS and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nature reviews Neuroscience. 2002; 3(5):383-394.
9. Naughton CK, Jain S, Strickland AM, Gupta A and Milbrandt J. Glial cell-line derived neurotrophic factor-mediated RET signaling regulates spermatogonial stem cell fate. Biology of reproduction. 2006; 74(2):314-321.
10. Bordeaux MC, Forcet C, Granger L, Corset V, Bidaud C, Billaud M, Bredesen DE, Edery P and Mehlen P. The RET proto-oncogene induces apoptosis: a novel mechanism for Hirschsprung disease. EMBO J. 2000; 19(15):4056-4063.
11. Dakhova O, Ozen M, Creighton CJ, Li R, Ayala G, Rowley D and Ittmann M. Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res. 2009; 15(12):3979-3989.
12. Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ and Frenette PS. Autonomic nerve development contributes to prostate cancer progression. Science. 2013; 341(6142):1236361.
13. Paratcha G and Ledda F. GDNF and GFRalpha: a versatile molecular complex for developing neurons. Trends in neurosciences. 2008; 31(8):384-391.
14. Gmyrek GA, Walburg M, Webb CP, Yu HM, You X, Vaughan ED, Vande Woude GF and Knudsen BS. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol. 2001; 159(2):579-590.
15. Hernandez-Vargas H, Palacios J and Moreno-Bueno G. Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle. 2007; 6(7):780-783.
16. Hernandez-Vargas H, Palacios J and Moreno-Bueno G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. Oncogene. 2007; 26(20):2902-2913.
17. Garzotto M, Myrthue A, Higano CS and Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol. 2006; 24(3):254-259.
18. Beer TM, Garzotto M, Lowe BA, Ellis WJ, Montalto MA, Lange PH and Higano CS. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2004; 10(4):1306-1311.
19. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol. 2000; 31(5):578-583.
20. Torok-Storb B, Iwata M, Graf L, Gianotti J, Horton H and Byrne MC. Dissecting the marrow microenvironment. Ann N Y Acad Sci. 1999; 872:164-170.
21. Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, Andersson AC, Angelidou P, Asplund A, Asplund C, Berglund L, Bergstrom K, Brumer H, Cerjan D, Ekstrom M, Elobeid A, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Molecular & cellular proteomics: MCP. 2005; 4(12):1920-1932.
22. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Bjorling L and Ponten F. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010; 28(12):1248-1250.
23. Trupp M, Ryden M, Jornvall H, Funakoshi H, Timmusk T, Arenas E and Ibanez CF. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J Cell Biol. 1995; 130(1):137-148.
24. Oatley JM, Avarbock MR and Brinster RL. Glial cell line-derived neurotrophic factor regulation of genes essential for self-renewal of mouse spermatogonial stem cells is dependent on Src family kinase signaling. J Biol Chem. 2007; 282(35):25842-25851.
25. Sariola H and Saarma M. Novel functions and signalling pathways for GDNF. J Cell Sci. 2003; 116(Pt 19):3855-3862.
26. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005; 437(7061):1032-1037.
27. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS and Knudsen KE. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 2010; 120(12):4478-4492.
28. Karantanos T, Corn PG and Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32(49):5501-5511.
29. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-28.
30. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis. 2008; 29(6):1092-1095.
31. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME. Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis. Science. 1995; 270(5240):1326-1331.
32. Allan LA, Morrice N, Brady S, Magee G, Pathak S and Clarke PR. Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol. 2003; 5(7):647-654.
33. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P and Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res. 2003; 159(4):439-452.
34. Paterlini-Brechot P and Benali NL. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Letters. 2007; 253(2):180-204.